TWI274585B - Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus - Google Patents

Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus Download PDF

Info

Publication number
TWI274585B
TWI274585B TW092114876A TW92114876A TWI274585B TW I274585 B TWI274585 B TW I274585B TW 092114876 A TW092114876 A TW 092114876A TW 92114876 A TW92114876 A TW 92114876A TW I274585 B TWI274585 B TW I274585B
Authority
TW
Taiwan
Prior art keywords
virus
flaviviridae
treating
pharmaceutical composition
infection
Prior art date
Application number
TW092114876A
Other languages
English (en)
Chinese (zh)
Other versions
TW200307558A (en
Inventor
Tsu-An Hsu
Yuan-Chin Tsai
Der-Ren Hwang
Original Assignee
Nat Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Health Research Institutes filed Critical Nat Health Research Institutes
Publication of TW200307558A publication Critical patent/TW200307558A/zh
Application granted granted Critical
Publication of TWI274585B publication Critical patent/TWI274585B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Packages (AREA)
TW092114876A 2002-06-03 2003-06-02 Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus TWI274585B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38503102P 2002-06-03 2002-06-03

Publications (2)

Publication Number Publication Date
TW200307558A TW200307558A (en) 2003-12-16
TWI274585B true TWI274585B (en) 2007-03-01

Family

ID=29550193

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092114876A TWI274585B (en) 2002-06-03 2003-06-02 Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus

Country Status (7)

Country Link
EP (1) EP1369120B1 (https=)
JP (1) JP2004131466A (https=)
KR (1) KR20030094097A (https=)
CN (1) CN1251687C (https=)
AT (1) ATE353658T1 (https=)
DE (1) DE60311702T2 (https=)
TW (1) TWI274585B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090058423A (ko) * 2007-12-04 2009-06-09 심형섭 소디움 메타아르세나이트를 함유하는 ｃ형 바이러스성 간염치료용 조성물
RU2518314C2 (ru) 2012-08-30 2014-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
TWI605822B (zh) * 2015-04-09 2017-11-21 高雄醫學大學 酪梨萃取物、ａｖｏｃａｄｅｎｏｌ Ｂ及（２Ｒ，４Ｒ）－１，２，４－三羥基十七碳－１６－炔的用途，以及包含酪梨萃取物之保健食品
EP3815699A1 (en) * 2019-10-28 2021-05-05 Technische Universität München New means and methods for therapy and diagnosis of adenoviral infection
MX2022010066A (es) * 2020-02-16 2022-08-25 Komipharm Int Australia Pty Ltd Metodo para tratamiento usando meta-arsenito.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9214419D0 (en) * 1992-07-07 1992-08-19 Concannon Peter Biocidal agents
JPH0769903A (ja) * 1993-07-01 1995-03-14 Hatsuchiyou:Kk 抗ヒト免疫不全ウイルス剤およびエイズ治療薬
WO1995011033A1 (en) * 1993-10-22 1995-04-27 Commonwealth Scientific And Industrial Research Organisation Polyoxometallates in the treatment of flavivirus infections
FR2786103A1 (fr) * 1998-10-30 2000-05-26 Assist Publ Hopitaux De Paris Utilisation de trioxyde d'arsenic pour la preparation d'un medicament destine a traiter les affections neoplastiques du tissu hematopoietique chez un mammifere et nouvelle composition pharmaceutique
JP4420997B2 (ja) * 1999-02-08 2010-02-24 利博 山瀬 抗ウィルス剤
CA2306039A1 (en) * 1999-04-19 2000-10-19 Schering Corporation Hcv combination therapy
JP2001233719A (ja) * 1999-12-13 2001-08-28 Natl Inst Of Advanced Industrial Science & Technology Meti 殺菌材および殺菌方法
EP1246629A4 (en) * 2000-01-06 2007-04-18 Marantech Holding Llc METHODS USING ACTIVE ELECTRON COMPOUNDS FOR MANAGING CANCER CONDITIONS
CA2451845A1 (en) * 2001-05-31 2002-12-05 The Cleveland Clinic Foundation Ptpase inhibitors and method of using same

Also Published As

Publication number Publication date
DE60311702D1 (de) 2007-03-29
DE60311702T2 (de) 2007-10-31
ATE353658T1 (de) 2007-03-15
CN1483413A (zh) 2004-03-24
EP1369120A1 (en) 2003-12-10
EP1369120B1 (en) 2007-02-14
TW200307558A (en) 2003-12-16
KR20030094097A (ko) 2003-12-11
CN1251687C (zh) 2006-04-19
JP2004131466A (ja) 2004-04-30

Similar Documents

Publication Publication Date Title
JP2024003097A (ja) コロナウイルス感染の治療におけるファビピラビルの使用
CA2853495A1 (en) Methods and compositions for treating hepatitis c virus
Meites et al. Fatal Clostridium sordellii infections after medical abortions
WO2021147273A1 (zh) 硝唑尼特及其活性形式替唑尼特在治疗SARS-CoV-2感染中的应用
Lee Page et al. Possible interaction between intravenous azithromycin and oral cyclosporine
TWI274585B (en) Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus
EP3785718A1 (en) Pharmaceutical composition for prevention or treatment of flavivirus infectious disease
Hiramatsu et al. Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?
ES2684396T3 (es) Heterociclil carboxamidas para tratar enfermedades víricas
CN114762694B (zh) 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用
CN101489579B (zh) 病毒性疾病的预防或治疗剂
US7482149B2 (en) Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
US20220016118A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
Fernández-Montero et al. Treatment of hepatitis C in HIV patients in the new era of direct-acting antivirals
KR20250054355A (ko) 경구용 c형간염 바이러스 치료제
Bzowej et al. A RANDOMIZED CONTROLLED TRIAL OF PROPHYLACTICALLY ADMINISTERED PEGINTERFERON ALFA-2A PLUS RIBAVIRIN VS NO PROPHYLAXIS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION (OLT) FOR HEPATITIS C: A REPORT OF INITIAL SAFETY AND TOLERABILITY: 2
WO2025183089A1 (ja) 潜伏感染しているｈｉｖを再活性化するための組成物
Xu et al. Initiation of Long-Acting Antiretroviral Combinations Achieve Sustained Virologic Remission in Early-Life SIV Infection
Huynh et al. Clinical Pharmacist’s Role in Successful Retreatment of Glecaprevir/Pibrentasvir Virologic Failure with Prolonged Treatment Duration and Low Dose Ribavirin in Hepatitis C Patient with End-Stage Renal Disease: A Case Report
Chevaliez et al. 744 IN VIVO AND IN VITRO RESISTANCE TO SILIBININ, A COMPONENT OF SILYMARIN AND POTENT INHIBITOR OF HCV REPLICATION
Bader et al. 742 ROSUVASTATIN COMPARED TO FLUVASTATIN, SIMVASTATIN, AND RIBAVIRIN FOR ANTI-HCV ACTIVITY IN VITRO
Bottecchia et al. 743 NATURALLY OCCURRING DRUG RESISTANCE MUTATIONS IN THE HEPATITIS C VIRUS NS3 PROTEASE IN HIV/HCV COINFECTED PATIENTS TREATED WITH HIV PROTEASE INHIBITORS
Lawitz et al. 997 Triple therapy compared to standard pegylated interferon alfa 2B+ weight based ribavirin for treatment naive chronic hepatitis C [tri-star trial]: final results
Stavar et al. Considerations on Direct Antiviral Agent Therapy in Patients Having Chronic Hepatitis C from Constanta County
Alvarez et al. 1013 Interferon treatment outcomes in patients with decompensated HCV+ cirrhosis

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees